5-6 Mai 2021<\/p>\n
Pietro Scalfaro, notre directeur m\u00e9dical, pr\u00e9sentera des r\u00e9sultats d’essais cliniques de notre compos\u00e9 principal Vonafexor au congr\u00e8s “Chronic Hepatitis B Drug Development Summit” : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.<\/p>\n
“This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection & mitigate related conditions such as fibrosis, cirrhosis, & hepatocellular carcinoma.”<\/p>\n
Plus de d\u00e9tails ici : https:\/\/chronic-hbv-summit.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" 5-6 Mai 2021<\/p>\n Pietro Scalfaro, notre directeur m\u00e9dical, pr\u00e9sentera des r\u00e9sultats d’essais cliniques de notre compos\u00e9 principal Vonafexor au congr\u00e8s “Chronic Hepatitis B Drug Development Summit” : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.<\/p>\n “This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection &<\/p>\n Lire la suite »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12],"tags":[],"class_list":["post-3645","post","type-post","status-publish","format-standard","hentry","category-events-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"\u00c9v\u00e9nements<\/a>","rttpg_excerpt":"5-6 Mai 2021 Pietro Scalfaro, notre directeur m\u00e9dical, pr\u00e9sentera des r\u00e9sultats d’essais cliniques de notre compos\u00e9 principal Vonafexor au congr\u00e8s “Chronic Hepatitis B Drug Development Summit” : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”. “This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug…","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3645"}],"version-history":[{"count":2,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3645\/revisions"}],"predecessor-version":[{"id":3647,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3645\/revisions\/3647"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}